Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of ABM-168 in Advanced Solid Tumors
NCT05831995Phase 1Terminated
- Sponsor
- ABM Therapeutics
- Start
- Mar 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of abm-168 in solid tumor (advanced stage), primary central nervous system tumor, melanoma and 3 more (3 arms), sponsored by ABM Therapeutics. Primary endpoints: Dose Limiting Toxicity and/or Recommended Phase 2 Dose, Safety and Tolerability (Incidence, Severity, Causality) and 5 more. Started Mar 2023; status: terminated.
02
Drugs
abm-168
03
Conditions
solid tumor (advanced stage)primary central nervous system tumormelanomacolon cancerlung cancer
Beyond the preview
Go deeper on NCT05831995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05831995.